Capital Wealth Planning LLC Sells 472,530 Shares of Amgen Inc. $AMGN

Posted by Trevor Kearing on Mar 14th, 2026

Capital Wealth Planning LLC lessened its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 36.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 825,780 shares of the medical research company’s stock after selling 472,530 shares during the quarter. Amgen makes up about 1.6% of Capital Wealth Planning LLC’s investment portfolio, making the stock its 23rd largest position. Capital Wealth Planning LLC owned 0.15% of Amgen worth $233,035,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of AMGN. Brighton Jones LLC lifted its holdings in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares during the period. Sivia Capital Partners LLC increased its stake in Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares during the period. Schnieders Capital Management LLC. raised its position in Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after purchasing an additional 5,853 shares in the last quarter. Impax Asset Management Group plc raised its position in Amgen by 139.8% in the second quarter. Impax Asset Management Group plc now owns 18,160 shares of the medical research company’s stock worth $5,070,000 after purchasing an additional 10,587 shares in the last quarter. Finally, Arvest Bank Trust Division lifted its stake in Amgen by 16.6% during the second quarter. Arvest Bank Trust Division now owns 827 shares of the medical research company’s stock worth $231,000 after purchasing an additional 118 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen (NASDAQ:AMGN) Earns Hold Rating from Analysts at Jefferies Financial Group
Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer‑term headwinds for the stock’s re-rating. Dividend Stock Analysis – Amgen, Inc.

Amgen Stock Performance

NASDAQ:AMGN opened at $366.21 on Friday. The stock has a market capitalization of $197.41 billion, a P/E ratio of 25.74, a price-to-earnings-growth ratio of 3.65 and a beta of 0.45. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The firm has a 50 day moving average of $357.73 and a 200-day moving average of $325.17.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same period in the prior year, the company earned $5.31 EPS. Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Analysts Set New Price Targets

AMGN has been the topic of a number of recent research reports. Oppenheimer set a $400.00 price objective on Amgen and gave the company an “outperform” rating in a report on Thursday, January 29th. Freedom Capital downgraded Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Guggenheim boosted their price target on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Leerink Partners reiterated a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Finally, Cantor Fitzgerald increased their price objective on Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $354.00.

Get Our Latest Stock Report on AMGN

Amgen Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.